A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated iron transport to the bone marrow. This multicenter, phase 1 study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of a fully humanized mAb (LY2787106) with high affinity for hepcidin in cancer patients with anemia. METHODS: Thirty-three patients with hepcidin levels ≥5 ng/mL received LY2787106 either every 3 weeks (19 patients, dose range 0.3-10 mg/kg) (part A) or weekly (14 patients, dose 10 mg/kg) (part B). LY2787106 PK/PD markers of iron and hematology biology were measured. RESULTS: LY2787106 clearance (32 mL/h) and volume of distribution (7.7 L) were independent of dose and time, leading to a dose-proportional increase in concentration with dose. Consistent dose-dependent increases in serum iron, and transferrin saturation were seen at the 3 and 10 mg/kg dose levels, typically peaking within 24 h after LY2787106 administration and returning to baseline by day 8. CONCLUSIONS: Our findings indicate that LY2787106 was well tolerated in cancer patients with anemia and that targeting the hepcidin-ferroportin pathway by neutralizing hepcidin resulted in transient iron mobilization, thus supporting the role of hepcidin in iron regulation. TRIAL REGISTRATION: ClinicalTrial.gov, NCT01340976.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“Hepcidin is a 25-amino-acid peptide that binds to ferroportin and causes internalization and degradation of the hepcidin-ferroportin complex, leading to decreased iron absorption and reduced iron export from macrophages [4].”
BackgroundInterleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · cited 1×
“Other studies have shown elevated levels of cytokines such as IL-6 in cancer patients with anemia [13], which may contribute to a lack of significant response in erythropoiesis and to an increase in hepcidin expression levels [14].”
BackgroundPrevalence and outcomes of anemia in cancer: a systematic review of the literature
Knight, K., Wade, S., & Balducci, L. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.008 · Cited by 878
Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin
Hohaus, S., Massini, G., Giachelia, M., Vannata, B., Bozzoli, V., Cuccaro, A., D'Alo', F., Larocca, L. M., Raymakers, R. A. P., Swinkels, D. W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6873 · Cited by 110 · cited 1×
“Other studies have shown elevated levels of cytokines such as IL-6 in cancer patients with anemia [13], which may contribute to a lack of significant response in erythropoiesis and to an increase in hepcidin expression levels [14].”
BackgroundA dual-monoclonal sandwich ELISA specific for hepcidin-25
Butterfield, A. M., Luan, P., Witcher, D. R., Manetta, J., Murphy, A. T., Wroblewski, V. J., & Konrad, R. J. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.151522 · Cited by 59
Research works printed but not linked: 9
- Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91(12):2214–21. · DOI · Paper page
- Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689–92. · DOI · Paper page
- Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14(11):3262–7. · DOI · Paper page
- Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, Ismail T, et al. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol. 2008;14(9):1339–45. · DOI · Paper page
- Arvedson TC, Li H, Rose MJ, Wang O, Sasu BJ. Evaluation of serum hepcidin concentrations in cancer and leukemia patients [abstract]. J Clin Oncol. 2008;26(15S):20581. · DOI
- Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278–83. · DOI · Paper page
- Boyce M, Warrington S, Cortezi B, Zöllner S, Vauléon S, Swinkels DW, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol. 2016. doi: 10.1111/bph.13433 . · DOI · Paper page
- Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836(2):245–54.
- Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28. · DOI · Paper page
Cited by
Iron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Ganz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Iron metabolism: pathophysiology and pharmacology
Roemhild, K., von Maltzahn, F., Weiskirchen, R., Knüchel, R., von Stillfried, S., & Lammers, T. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.05.001 · Cited by 302
Metadata
- Authors
- Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., Tiu, R. V., Wang, X., Callies, S., Cox, J., Tuttle, J. L., Lau, Y.-K., & Roeland, E. J.
- Venue
- Journal of Hematology & Oncology
- Published
- 2017-03-21
- Volume
- 10
- Issue
- 1
- Pages
- 73-73
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W2598663185
- Cited by
- 89
- References
- 5
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- Eli Lilly and Company
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. https://app.cochat.ai/papers/10.1186/s13045-017-0427-x
- The paper
- Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., Tiu, R. V., Wang, X., Callies, S., Cox, J., Tuttle, J. L., Lau, Y.-K., & Roeland, E. J. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-017-0427-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.